Pesquisar
Neumora Therapeutics Inc
NMRAAdicionar à lista de desejos
0.703USD
-0.028-3.83%
Fechamento 09-23 16:00（ET）
130.25MValor de mercado
PerdaP/L TTM
Sobre o Neumora Therapeutics Inc Empresa
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Neumora Therapeutics Inc Perfil
Código da empresaNMRA
Nome da EmpresaNeumora Therapeutics Inc
Data de listagemSep 15, 2023
CEOBerns (Paul L)
Número de funcionários110
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 15
Endereço260 Arsenal Place, Suite 1
CidadeWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Telefone18577600900
Sitehttps://neumoratx.com/
Código da empresaNMRA
Data de listagemSep 15, 2023
CEOBerns (Paul L)
Executivos da empresa Neumora Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul L. Berns
Mr. Paul L. Berns
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
7.71M
+0.56%
Mr. Paul L. Berns
Mr. Paul L. Berns
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
7.71M
+0.56%
Mr. Paul L. Berns
Mr. Paul L. Berns
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul L. Berns
Mr. Paul L. Berns
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
7.71M
+0.56%
Mr. Paul L. Berns
Mr. Paul L. Berns
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
7.71M
+0.56%
Mr. Paul L. Berns
Mr. Paul L. Berns
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Neumora Therapeutics Inc?
Os cinco principais acionistas de Neumora Therapeutics Inc são: Mr. Paul L. Berns
Quantas instituições possuem ações da Neumora Therapeutics Inc (NMRA)?
Em 2026Q1, 301 instituições possuíam ações da Neumora Therapeutics Inc, com valor de mercado aproximado de 106.55M, representando 57.52% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -16535931.00.